Search

for
Search:

Research

5 / 1000+ results

Protac Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration

research PROTAC Degraders of Androgen Receptor‐Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration

December 2022 in “Small methods”

A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.

research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One

10 citations , July 2022 in “Journal of Medicinal Chemistry”

Adding a second method to PROTACs could improve cancer treatment.

research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment

3 citations , October 2025 in “Cancer”

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions

9 citations , October 2025 in “MedComm”

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

research Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery

November 2025 in “Journal of Medicinal Chemistry”

Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.

View more "ar-proteolysis targeting chimera" in research →

Community Join

3 / 1000+ results

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

in Research/Science 133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁

in Treatment 274 upvotes 4 months ago

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

community Is GT20029 supposed to regrow hair as well?

in Treatment 11 upvotes 3 years ago

The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

View more "ar-proteolysis targeting chimera" in community →

Learn

2 / 801 results

learn GT20029

research compound made to degrade androgen receptors in scalp

learn oligopeptide-71

View more "ar-proteolysis targeting chimera" in learn →

Clinics

6 / 9 results

Experts

1 / 4 results

36
Hair Transplant Surgeon
Dr. Shashikiran AR, MD, MBBS, FRGHS
Mysuru, Karnataka, India

Dr. Shashikiran AR, MD, MBBS, FRGHS